Drug Trial Radar · NCT00243672
Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques
Last checked: Nov 20, 2026Latest source record: Nov 19, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 2005
Primary completion
Not stated
Study completion Oct 2007
Sponsor
- Lead sponsor
- University Hospital MuensterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 24, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rupture of unstable atherosclerotic plaques is the underlying pathophysiologic mechanism of acute coronary syndromes and thus also of perioperative myocardial ischemia. Lipid lowering drugs such as statins and fibrates have been shown to improve the outcomes of patients with atherosclerosis. This is not only mediated through their therapeutic actions on lipid metabolism, but relies on a multitude of pleiotropic effects of these substances. One of the most interesting of these effects is the stabilisation of atherosclerotic plaques. To investigate these effects in a perioperative setting, patients scheduled for thromboendarterectomy of the carotid artery will be recruited. They will be randomised to receive either atorvastatin 10mg/d, gemfibrozil 1200mg/d or placebo for two weeks preoperatively. Specimens of carotid plaques will be obtained intraoperatively. After microscopic characterisation of plaques, DNA-microarray analyses will be done to gain insights into the transcriptional regulation and expression profiles of various types of atherosclerotic plaques under different pharmacological circumstances (stable or unstable with statin/fibrate/placebo).
Conditions
- Atherosclerosis
Interventions
AtorvastatinDrug
GemfibrozilDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- expression profile in atherosclerotic plaque
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.